New supercluster to bring life to UK translational research
This article was originally published in Scrip
A new UK life sciences super cluster will help strengthen partnerships between academia, industry and the NHS, according to Lifescience 2010: Delivering the Blueprint, a UK government report published this week.
You may also be interested in...
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.